Save 20% on All Global Market Reports With Code ONLINE20 – Gain Insights Into Tariffs, Inflation, and Industry Trends
What Is the Forecast Market Size and Growth Rate of the Nucleic Acid Therapeutics Market by Region?
The nucleic acid therapeutics market size has grown rapidly in recent years. It will grow from $6.01 billion in 2024 to $6.94 billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to increasing prevalence of genetic and chronic diseases, growing research and development in genomics, rising adoption of RNA-based therapeutics, increasing support from academic and government institutions, and growing success of mRNA vaccine platforms.
The nucleic acid therapeutics market size is expected to see rapid growth in the next few years. It will grow to $12.24 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to rising demand for precision medicine, expansion of mRNA vaccine applications beyond COVID-19, the rise of next-gen delivery platforms, a growing pipeline of nucleic acid-based drugs, and increasing approvals from regulatory agencies. Major trends in the forecast period include expansion of mRNA platforms into oncology and rare diseases, integration of AI and machine learning in RNA drug discovery, development of targeted delivery systems for tissue-specific action, modular and multi-target platform therapies, and next-generation aptamer technologies.
Claim your free report sample now:
Who Are the Major Contributors to the Nucleic Acid Therapeutics Market Growth?
The increasing number of genetic and chronic diseases is expected to propel the growth of the nucleic acid therapeutics market going forward. Genetics and chronic diseases refer to the relationship between inherited genetic factors and the development, progression, or risk of long-term health conditions such as diabetes, cardiovascular diseases, cancer, and autoimmune disorders. The rise in genetics-related and chronic diseases is largely due to improved diagnostic technologies that identify these conditions more accurately and earlier. Nucleic acid therapeutics are useful for genetics and chronic diseases because they can target and modify the underlying genetic causes of these conditions by regulating, repairing, or silencing specific genes, offering precise and personalized treatment options. For instance, October 2024, according to the Cystic Fibrosis Trust is a UK-based charity dedicated to supporting people with cystic fibrosis, in 2022, 11,148 cystic fibrosis patients were registered, and this number grew to 11,318 in 2023, reflecting a 1.5% increase in patient registrations year-over-year. Therefore, the increasing number of genetic and chronic diseases is driving the growth of the nucleic acid therapeutics market.
How Is the Nucleic Acid Therapeutics Market Divided by Type and Application?
The nucleic acid therapeutics market covered in this report is segmented
1) By Therapy Type: Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Gene Therapies, Aptamers, Other Therapy Types
2) By Therapeutic Area: Neuromuscular Disorder, Metabolic Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Oncological Disorders, Other Therapeutic Areas
3) By Route Of Administration: Intravenous, Subcutaneous, Other Route Of Administrations
4) By Delivery Method: Viral Vector-Based Delivery Systems, Non-Viral Delivery Systems
5) By End-Use: Pharmaceutical Companies, Government And Academic Research Institutes, Biotech Companies
Subsegment:
1) By Antisense Oligonucleotides (ASOs): Phosphorothioate ASOs, 2’-O-Methyl ASOs, Locked Nucleic Acid (LNA) ASOs, Gapmer ASOs, Morpholino ASOs
2) By Small Interfering RNA (siRNA): Lipid Nanoparticle (LNP) Formulated siRNA, GalNAc-Conjugated siRNA, Chemically Modified siRNA, Naked siRNA
3) By Gene Therapies: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, CRISPR-Based Gene Therapy, Zinc Finger Nucleases (ZFNs), TALENs
4) By Aptamers: Ribonucleic Acid (RNA) Aptamers, Deoxyribonucleic Acid (DNA) Aptamers, Spiegelmers, Pegylated Aptamers
5) By Others Therapy Types: MicroRNA (miRNA) Therapeutics, Long Non-Coding RNA (lncRNA) Therapeutics, Ribonucleic Acid (RNA) Editing Therapies, Ribozymes
What Are the Future Trends Forecasted for the Nucleic Acid Therapeutics Market?
Major companies operating in the nucleic acid therapeutics market are focusing on developing innovative products such as antisense oligonucleotide therapy to target and silence specific disease-causing genes, offering precision treatment options for genetic disorders and rare diseases. Antisense oligonucleotide therapy is a precision treatment that uses short, synthetic strands of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to block or modify the expression of specific genes involved in disease. For instance, in December 2024, Ionis Pharmaceuticals Inc., a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for TRYNGOLZ (olezarsen) as an adjunct therapy to diet for lowering triglyceride levels in adults diagnosed with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by severe hypertriglyceridemia (sHTG) and a high risk of acute pancreatitis (AP). It represents the first FDA-approved treatment to deliver significant and sustained triglyceride reduction in this patient population, alongside a clinically meaningful decrease in AP incidence when combined with a low-fat diet. The therapy is designed for convenient self-administration via a once-monthly auto-injector.
Who Are the Emerging Players in the Nucleic Acid Therapeutics Market?
Major companies operating in the nucleic acid therapeutics market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Moderna Inc., BioNTech SE, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Imugene Limited, CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc., and Exothera S.A.
Get the full nucleic acid therapeutics market report here:
How Is Regional Performance Expected to Affect Nucleic Acid Therapeutics Market Growth?
North America was the largest region in the nucleic acid therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment